Works about DAPAGLIFLOZIN
Results: 1120
沙格列汀与达格列净分别联合阿法骨化醇对 T2DM 性骨质 疏松症患者疗效和 25- 羟维生素 D 水平， 骨代谢指标的影响.
- Published in:
- Progress in Modern Biomedicine, 2025, v. 25, n. 3, p. 468, doi. 10.13241/j.cnki.pmb.2025.03.009
- By:
- Publication type:
- Article
Integrated Omics Insights into Dapagliflozin Effects in Sepsis-Induced Cardiomyopathy.
- Published in:
- Biomolecules (2218-273X), 2025, v. 15, n. 2, p. 286, doi. 10.3390/biom15020286
- By:
- Publication type:
- Article
Exploring Kidney Oxygenation Responses to Dapagliflozin, Exenatide, and Their Combination in Patients With Type 2 Diabetes and Chronic Kidney Disease: Observations From a Prespecified Pilot Study of a Randomized Crossover Trial.
- Published in:
- 2025
- By:
- Publication type:
- Letter
Efficacy of Dapagliflozin in the Treatment of Type 2 Diabetes Mellitus Complicated by Coronary Heart Disease: A Meta-Analysis.
- Published in:
- British Journal of Hospital Medicine (17508460), 2025, v. 86, n. 2, p. 1, doi. 10.12968/hmed.2024.0336
- By:
- Publication type:
- Article
New pharmacological approaches to diabetes management.
- Published in:
- Practice Nursing, 2015, v. 26, n. 3, p. 140, doi. 10.12968/pnur.2015.26.3.140
- By:
- Publication type:
- Article
Dapagliflozin for Atrial Fibrillation.
- Published in:
- Cardiovascular Drugs & Therapy, 2024, v. 38, n. 1, p. 1, doi. 10.1007/s10557-024-07543-7
- By:
- Publication type:
- Article
The SGLT2i Dapagliflozin Reduces RV Mass Independent of Changes in RV Pressure Induced by Pulmonary Artery Banding.
- Published in:
- Cardiovascular Drugs & Therapy, 2024, v. 38, n. 1, p. 57, doi. 10.1007/s10557-022-07377-1
- By:
- Publication type:
- Article
Effect of Dapagliflozin on the Outcome of Radiofrequency Catheter Ablation in Patients with Type 2 Diabetes Mellitus and Atrial Fibrillation.
- Published in:
- Cardiovascular Drugs & Therapy, 2024, v. 38, n. 1, p. 91, doi. 10.1007/s10557-022-07368-2
- By:
- Publication type:
- Article
Ticagrelor and Dapagliflozin Have Additive Effects in Ameliorating Diabetic Nephropathy in Mice with Type-2 Diabetes Mellitus.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 5, p. 829, doi. 10.1007/s10557-021-07222-x
- By:
- Publication type:
- Article
SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 6, p. 1091, doi. 10.1007/s10557-021-07243-6
- By:
- Publication type:
- Article
Dapagliflozin and the initial glomerular filtration rate decline in advanced-stage non-diabetic chronic kidney disease.
- Published in:
- Clinical & Experimental Nephrology, 2022, v. 26, n. 12, p. 1242, doi. 10.1007/s10157-022-02260-7
- By:
- Publication type:
- Article
Sodium‐glucose co‐transporter‐2 inhibitors and the risk of venous thromboembolism: A nationwide population‐based study and meta‐analysis.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2024, v. 40, n. 2, p. 1, doi. 10.1002/dmrr.3739
- By:
- Publication type:
- Article
A meta‐analysis of randomized controlled trials evaluating sodium‐glucose co‐transporter 2 inhibitors and incidental atrial fibrillation—Is there a true benefit?
- Published in:
- Diabetes/Metabolism Research & Reviews, 2024, v. 40, n. 1, p. 1, doi. 10.1002/dmrr.3715
- By:
- Publication type:
- Article
Dapagliflozin improves pancreatic islet function by attenuating microvascular endothelial dysfunction in type 2 diabetes.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2023, v. 39, n. 3, p. 1, doi. 10.1002/dmrr.3607
- By:
- Publication type:
- Article
Glucagon in type 1 diabetes patients receiving SGLT2 inhibitors: A Friend or Foe?
- Published in:
- Diabetes/Metabolism Research & Reviews, 2021, v. 37, n. 5, p. 1, doi. 10.1002/dmrr.3415
- By:
- Publication type:
- Article
Managing type 2 diabetes mellitus during COVID‐19 pandemic: The bittersweet.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2021, v. 37, n. 1, p. 1, doi. 10.1002/dmrr.3360
- By:
- Publication type:
- Article
Comparative effectiveness of dapagliflozin vs DPP‐4 inhibitors on a composite endpoint of HbA1c, body weight and blood pressure reduction in the real world.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2021, v. 37, n. 1, p. 1, doi. 10.1002/dmrr.3353
- By:
- Publication type:
- Article
UHPLC Method Development for Determining Sitagliptin and Dapagliflozin in Lipid-Based Self-Nanoemulsifying Systems as Combined Dose in Commercial Products and its Application to Pharmacokinetic Study of Dapagliflozin in Rats.
- Published in:
- Pharmaceutical Chemistry Journal, 2019, v. 53, n. 1, p. 79, doi. 10.1007/s11094-019-01959-4
- By:
- Publication type:
- Article
Forxiga (dapagliflozin): Plausible role in the treatment of diabetes-associated neurological disorders.
- Published in:
- Biotechnology & Applied Biochemistry, 2016, v. 63, n. 1, p. 145, doi. 10.1002/bab.1319
- By:
- Publication type:
- Article
Effect of dapagliflozin on oxidative stress in heart embryonic H9c2 cardiomyocytes.
- Published in:
- International Journal of Medical Biochemistry, 2024, v. 7, n. 1, p. 6, doi. 10.14744/ijmb.2024.49368
- By:
- Publication type:
- Article
Dapagliflozin in Heart Failure with Reduced Ejection Fraction: A Real-World Study.
- Published in:
- Cardiovascular Innovations & Applications (CVIA), 2022, v. 6, n. 4, p. 219, doi. 10.15212/CVIA.2022.0005
- By:
- Publication type:
- Article
DIABETES, CEREBROVASCULAR DISEASES, KIDNEY DISEASES, CARDIO-ONCOLOGY.
- Published in:
- Cardiovascular Innovations & Applications (CVIA), 2021, v. 6, p. C115
- Publication type:
- Article
Journal Scan.
- Published in:
- 2022
- By:
- Publication type:
- Abstract
Potential impact of sodium glucose co-transporter (SGLT2) inhibitors on cholesterol fractions in stage 3 chronic kidney disease.
- Published in:
- Egyptian Journal of Internal Medicine, 2024, v. 36, n. 1, p. 1, doi. 10.1186/s43162-024-00352-2
- By:
- Publication type:
- Article
Highlights from the 59<sup>th</sup> Annual Meeting of the European Association for the Study of Diabetes.
- Published in:
- Diabetes & Primary Care, 2023, v. 25, n. 5, p. 149
- Publication type:
- Article
SGLT2 inhibitors: Indications, doses and licences in adults.
- Published in:
- Diabetes & Primary Care, 2023, v. 25, n. 1, p. 9
- Publication type:
- Article
Signed, sealed and DELIVERed.
- Published in:
- Diabetes & Primary Care, 2022, v. 24, n. 5, p. 167
- By:
- Publication type:
- Article
SGLT2 inhibitors: Indications, doses and licences (England, Scotland and Wales).
- Published in:
- Diabetes & Primary Care, 2021, v. 23, n. 6, p. 175
- Publication type:
- Article
Highlights from the 2021 EASD Annual Meeting. Part 1.
- Published in:
- Diabetes & Primary Care, 2021, v. 23, n. 5, p. 153
- Publication type:
- Article
Drugs in development and new data on established drugs: Highlights from the American Diabetes Association 81st Scientific Sessions.
- Published in:
- Diabetes & Primary Care, 2021, v. 23, n. 4, p. 115
- Publication type:
- Article
News from the 2020 EASD Annual Meeting.
- Published in:
- Diabetes & Primary Care, 2020, v. 22, n. 5, p. 115
- By:
- Publication type:
- Article
News from the 2020 ADA conference.
- Published in:
- Diabetes & Primary Care, 2020, v. 22, n. 3, p. 53
- Publication type:
- Article
Updates from EASD 2017.
- Published in:
- Diabetes & Primary Care, 2017, v. 19, n. 5, p. 190
- Publication type:
- Article
Dapagliflozin Versus Insulin: Which Is Better in Treatment of Diabetic Nephropathy in Albino Rats, Immunohistochemical Study.
- Published in:
- Egyptian Academic Journal of Biological Sciences. D, Histology & Histochemistry, 2022, v. 14, n. 1, p. 95, doi. 10.21608/EAJBSD.2022.221869
- By:
- Publication type:
- Article
Prescribing patterns and factors associated with sodium–glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease.
- Published in:
- CMAJ Open, 2023, v. 11, n. 3, p. E494, doi. 10.9778/cmajo.20220039
- By:
- Publication type:
- Article
Effects of Dapagliflozin Adjunct to Insulin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized, Controlled, Open-Labeled Trial.
- Published in:
- BioMed Research International, 2021, p. 1, doi. 10.1155/2021/6618257
- By:
- Publication type:
- Article
DELIVER: Extending the benefits of SGLT-2 inhibitors.
- Published in:
- Global Cardiology Science & Practice, 2023, v. 2023, n. 3, p. 1, doi. 10.21542/gcsp.2023.21
- By:
- Publication type:
- Article
Combination of dapagliflozin and pioglitazone lacks superiority against monotherapy in streptozotocin-induced nephropathy.
- Published in:
- Scientific Reports, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41598-024-84487-w
- By:
- Publication type:
- Article
Effects of dapagliflozin on myoglobin efflux from cardiomyocyte during myocardial ischemia/reperfusion in anesthetized rats.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-67195-3
- By:
- Publication type:
- Article
Dapagliflozin Improves Angiogenesis after Hindlimb Ischemia through the PI3K-Akt-eNOS Pathway.
- Published in:
- Biomolecules (2218-273X), 2024, v. 14, n. 5, p. 592, doi. 10.3390/biom14050592
- By:
- Publication type:
- Article
SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate.
- Published in:
- Biomolecules (2218-273X), 2020, v. 10, n. 11, p. 1573, doi. 10.3390/biom10111573
- By:
- Publication type:
- Article
Efficacy and safety of sodium–glucose co‐transporter‐2 inhibitors in kidney transplant recipients with diabetes mellitus.
- Published in:
- Diabetic Medicine, 2024, v. 41, n. 8, p. 1, doi. 10.1111/dme.15383
- By:
- Publication type:
- Article
Dapagliflozin improves erectile dysfunction in patients with type 2 diabetes mellitus: An open‐label, non‐randomized pilot study.
- Published in:
- Diabetic Medicine, 2024, v. 41, n. 1, p. 1, doi. 10.1111/dme.15217
- By:
- Publication type:
- Article
Implementation of dapagliflozin as adjunctive therapy in type 1 diabetes: A single centre real‐world experience.
- Published in:
- 2022
- By:
- Publication type:
- Letter to the Editor
The change in glycaemic control immediately after COVID‐19 vaccination in people with type 1 diabetes.
- Published in:
- Diabetic Medicine, 2022, v. 39, n. 4, p. 1, doi. 10.1111/dme.14774
- By:
- Publication type:
- Article
Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease.
- Published in:
- Diabetic Medicine, 2022, v. 39, n. 4, p. 1, doi. 10.1111/dme.14769
- By:
- Publication type:
- Article
The cost‐effectiveness of dapagliflozin compared to DPP‐4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands.
- Published in:
- Diabetic Medicine, 2021, v. 38, n. 4, p. 1, doi. 10.1111/dme.14371
- By:
- Publication type:
- Article
Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations on the use of sodium–glucose cotransporter inhibitors with insulin for treatment of type 1 diabetes (Updated October 2020).
- Published in:
- Diabetic Medicine, 2021, v. 38, n. 2, p. 1, doi. 10.1111/dme.14458
- By:
- Publication type:
- Article
Renal outcomes with the newer antidiabetes drugs: the era before and after CREDENCE.
- Published in:
- Diabetic Medicine, 2020, v. 37, n. 4, p. 593, doi. 10.1111/dme.14262
- By:
- Publication type:
- Article
News and Views: Update on technologies, medicines and treatments.
- Published in:
- Diabetic Medicine, 2019, v. 36, n. 7, p. 913, doi. 10.1111/dme.13965
- By:
- Publication type:
- Article